A 2-year prospective cohort study of antidementia drug non-persistency in mild-to-moderate Alzheimer's disease in Europe: Predictors of discontinuation and switch in the ICTUS study

CNS Drugs

Volumn 28, Issue 2, 2014, Pages 157-170

  Gardette, Virginie ^a,b,c   Lapeyre Mestre, Maryse ^a,b,c   Piau, Antoine ^c   Gallini, Adeline ^a,b,c   Cantet, Christelle ^a,b,c   Montastruc, Jean Louis ^a,b,c   Vellas, Bruno ^a,b,c   Andrieu, Sandrine ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE; CHOLINESTERASE INHIBITOR;

AGED; ALZHEIMER DISEASE; ARTICLE; BODY MASS; COHORT ANALYSIS; DAILY LIFE ACTIVITY; DEATH; DISEASE DURATION; DISEASE EXACERBATION; DISEASE INSTITUTIONALIZATION; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EUROPE; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; OUTCOME ASSESSMENT; PHYSICIAN; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; STRUCTURED QUESTIONNAIRE; UNSPECIFIED SIDE EFFECT; KAPLAN MEIER METHOD; MEDICATION COMPLIANCE; NEUROPSYCHOLOGICAL TEST; PROGNOSIS; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COHORT STUDIES; EUROPE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MEDICATION ADHERENCE; NEUROPSYCHOLOGICAL TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84896839102     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-013-0133-3     Document Type: Article

References (45)

1. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006;(2):CD003154.
2. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006;(1):CD005593.
3. Doody RS, Dunn JK, Clark CM, Farlow M, Foster NL, Liao T, et al. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord. 2001;12(4):295-300.
4. Rogers SL, Doody RS, Pratt RD, Ieni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol. 2000;10(3):195-203.
5. Burns A, Gauthier S, Perdomo C. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2007;22(8):806-12.
6. Daiello LA, Ott BR, Lapane KL, Reinert SE, Machan JT, Dore DD. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia. Am J Geriatr Pharmacother. 2009;7(2):74-83.
7. Gauthier S, Patterson C, Chertkow H, Gordon M, Herrmann N, Rockwood K, et al. Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4). Can Geriatr J. 2012;15(4):120-6.
8. Abughosh SM, Kogut SJ. Comparison of persistence rates of acetylcholine-esterase inhibitors in a state Medicaid program. Patient Prefer Adherence. 2008;2:79-85.
9. Amuah JE, Hogan DB, Eliasziw M, Supina A, Beck P, Downey W, et al. Persistence with cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer's disease. Pharmacoepidemiol Drug Saf. 2010;19(7):670-9.
10. Brewer L, Bennett K, McGreevy C, Williams D. A population-based study of dosing and persistence with anti-dementia medications. Eur J Clin Pharmacol. 2013;69(7):1467-75.
11. Gadzhanova S, Roughead L, Mackson J. Anticholinesterase duration in the Australian veteran population. Aust N Z J Psychiatry. 2010;44(5):469-74.
12. Herrmann N, Binder C, Dalziel W, Smyth S, Camacho F. Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database study. Drugs Aging. 2009;26(5):403-7.
13. Herrmann N, Gill SS, Bell CM, Anderson GM, Bronskill SE, Shulman KI, et al. A population-based study of cholinesterase inhibitor use for dementia. J Am Geriatr Soc. 2007;55(10):1517-23.
14. Kogut SJ, El-Maouche D, Abughosh SM. Decreased persistence to cholinesterase inhibitor therapy with concomitant use of drugs that can impair cognition. Pharmacotherapy. 2005;25(12):1729-35.
15. Kroger E, van Marum R, Souverein P, Egberts T. Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: a retrospective cohort study. Drugs Aging. 2010;27(8):663-75.
16. Le Couteur DG, Robinson M, Leverton A, Creasey H, Waite L, Atkins K, et al. Adherence, persistence and continuation with cholinesterase inhibitors in Alzheimer's disease. Australas J Ageing. 2012;31(3):164-9.
17. Massoud F, Desmarais JE, Gauthier S. Switching cholinesterase inhibitors in older adults with dementia. Int Psychogeriatr. 2011;23(3):372-8.
18. Mucha L, Shaohung S, Cuffel B, McRae T, Mark TL, Del Valle M. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease. J Manag Care Pharm. 2008;14(5):451-61.
19. Pariente A, Pinet M, Moride Y, Merliere Y, Moore N, Fourrier-Reglat A. Factors associated with persistence of cholinesterase inhibitor treatments in the elderly. Pharmacoepidemiol Drug Saf. 2010;19(7):680-6.
20. Singh G, Thomas SK, Arcona S, Lingala V, Mithal A. Treatment persistency with rivastigmine and donepezil in a large state medicaid program. J Am Geriatr Soc. 2005;53(7):1269-70.
21. Suh DC, Thomas SK, Valiyeva E, Arcona S, Vo L. Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer's disease. Drugs Aging. 2005;22(8):695-707.
22. Sun Y, Lai MS, Lu CJ, Chen RC. How long can patients with mild or moderate Alzheimer's dementia maintain both the cognition and the therapy of cholinesterase inhibitors: a national population-based study. Eur J Neurol. 2008;15(3):278-83.
23. Mauskopf JA, Paramore C, Lee WC, Snyder EH. Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings. J Manag Care Pharm. 2005;11(3):231-51.
24. Frankfort SV, Appels BA, de Boer A, Tulner LR, van Campen JP, Koks CH, et al. Discontinuation of rivastigmine in routine clinical practice. Int J Geriatr Psychiatry. 2005;20(12):1167-71.
25. Gardette V, Andrieu S, Lapeyre-Mestre M, Coley N, Cantet C, Ousset PJ, et al. Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer's disease: a 2-year prospective, multicentre, cohort study. CNS Drugs. 2010;24(5):431-42.
26. Umegaki H, Itoh A, Suzuki Y, Nabeshima T. Discontinuation of donepezil for the treatment of Alzheimer's disease in geriatric practice. Int Psychogeriatr. 2008;20(4):800-6.
27. Saleh S, Kirk A, Morgan DG, Karunanayake C. Less education predicts anticholinesterase discontinuation in dementia patients. Can J Neurol Sci. 2013;40(5):684-90.
28. Haider B, Schmidt R, Schweiger C, Forstner T, Labek A, Lampl C. Medication adherence in patients with dementia: an Austrian cohort study. Alzheimer Dis Assoc Disord. Epub 9 Oct 2013.
29. Dybicz SB, Keohane DJ, Erwin WG, McRae T, Shah SN. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis. Am J Geriatr Pharmacother. 2006;4(2):154-60.
30. Reynish E, Cortes F, Andrieu S, Cantet C, Olde Rikkert M, Melis R, et al. The ICTUS Study: a prospective longitudinal observational study of 1,380 AD patients in Europe. Study design and baseline characteristics of the cohort. Neuroepidemiology. 2007;29(1-2):29-38.
31. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-44.
32. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-98.
33. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566-72.
34. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA. 1963;21(185):914-9.
35. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308-14.
36. Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist. 1980;20(6):649-55.
37. WHO Collaborating Centre for Drug Statistics Methodology. About the ATC/DDD system. Oslo, Norway.
38. Olazaran J, Navarro E, Rojo JM. Persistence of cholinesterase inhibitor treatment in dementia: insights from a naturalistic study. Dement Geriatr Cogn Dis Extra. 2013;3(1):48-59.
39. Gardarsdottir H, Heerdink ER, Egberts AC. Potential bias in pharmacoepidemiological studies due to the length of the drug free period: a study on antidepressant drug use in adults in the Netherlands. Pharmacoepidemiol Drug Saf. 2006;15(5):338-43.
40. Herrmann N, Black SE, Li A, Lanctot KL. Discontinuing cholinesterase inhibitors: results of a survey of Canadian dementia experts. Int Psychogeriatr. 2011;23(4):539-45.
41. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293(5):596-608.
42. Ray R, Prettyman R. When do we discontinue anti-dementia drugs? Views expressed by clinicians in a national survey within the United Kingdom. Int Psychogeriatr. 2013;17:1-2.
43. Oude Voshaar RC, Burns A, Olde Rikkert MG. Alarming arbitrariness in EU prescription and reimbursement criteria for anti-dementia drugs. Int J Geriatr Psychiatry. 2006;21(1):29-31.
44. Fauth EB, Gibbons A. Which behavioral and psychological symptoms of dementia are the most problematic? Variability by prevalence, intensity, distress ratings, and associations with caregiver depressive symptoms. Int J Geriatr Psychiatry. Epub 12 Jul 2013.
45. Schwalbe O, Scheerans C, Freiberg I, Schmidt-Pokrzywniak A, Stang A, Kloft C. Compliance assessment of ambulatory Alzheimer patients to aid therapeutic decisions by healthcare professionals. BMC Health Serv Res. 2010;10:232.